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Prophylactic Nurturing of Antibiotic Resistance Genes
S. Soleimani-Connolly ∗, S.N. Connolly
University of Teesside, Middlesbrough, United Kingdom
Prophylaxis with the anti-staphylococcal antibiotic
mupirocin (Mup) introduced to Iran during 1995 led to the
rapid emergence of resistant strains. This study reports
that conjugative plasmids in coagulase negative staphy-
lococci (CNS) act as a reservoir of mupirocin resistance
(MupR) genes. The resistant elements are transferable to
pathogenic S. aureus strains leading to the dissemination of
resistance.
Staphylococci (1404 strains) were isolated from patients
attending a renal dialysis clinic over a period of 12 months
pre- and post-prophylactic application of Mup. Plasmid pro-
ﬁles & antibiograms of MupR strains were determined and
the resistance plasmids eliminated by curing. Conjugative
transfer of MupR involved ﬁlter mating to a reference
S. aureus strain. Pulsed ﬁeld gel electrophoresis (PFGE)
demonstrated the MupR plasmid. The MupR gene was cloned
into S. carnosus and a digoxigenin labeled 13.4 kb HindIII
fragment was used as a probe to screen other staphylococcal
isolates.
Staphylococcal strains consisting of S. epidermidis (1119)
and S. hominis (285) were isolated over a period of 14
months. Nasal decolonisation with Mup involved topical
application for 12 days. Eight high level resistance strains
(2000mg L−1) emerged within 4 months of clinical applica-
tion of the antibiotic. PFGE separated a large plasmid from
chromosomal DNA. Curing experiments conﬁrmed that this
plasmid was responsible for MupR as its elimination in the
cured strains rendered them Mup sensitive. High level MupR
was attributed to a 34 kb conjugative plasmid transferable
between CNS and S. aureus. The frequency of transfer was
of the order of 10−7 to 10−9. A 3.9 kb fragment of the MupR
plasmid hybridised to the probe DNA.
MupR develops during topical application of the antibiotic
and the transfer of the Mup gene occurs between CNS and
pathogenic staphylococci. This suggests that antibiotic pro-
phylaxis nurtures dormant genes thus leading to the spread
of resistance in non-endemic regions.
doi:10.1016/j.ijid.2008.05.1078
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Antibacterial Activity of Terminalia catappa Against Bac-
teria Isolated from Burn Wounds and Comparison with
Effects of Selective Antibiotics in vitro
M.M. Attarpour Yazdi1,∗, M. Kamalinejad2
1 Shahed University(Faculty of Medicine), Tehran, Iran
(Islamic Republic of)
2 Shahid Beheshti University(Faculty of Pharmacy), Tehran,
Iran (Islamic Republic of)
Background: Burn wound is suitable site for incidence of
resistant infections. Thus, the research for ﬁnding of effec-
tive drugs against this problem is necessary. Medicinal herbs
with antimicrobial activity have been important role in tra-
ditional medicine. The purpose of this study was determine
of antibacterial activity of methanolic extract from fruit
of Terminalia catappa against bacteria isolated from burn
wound infections and comparison with effects of selective
antibiotics in vitro.
Methods: First, a sample of methanolic extract of the
plant fruit was prepared and then its antibacterial activity
against 8 cases of bacteria isolated from 100 samples of burn
wound infections was evaluated by well diffusion and agar
serial dilution methods for determining of MIC (minimum
inhibitory concentration). Also, we studied the activity of
selective antibiotics on them by disk diffusion method
Results: The frequency distribution tables, diagrams,
Kay square, ﬁsher exact and t test (by applying spss
computer programs) were used to describe and ana-
lyze the data. The results from the antibacterial tests
demonstrated that the T. catappa methanolic extract had
been effected against more than 80% of Staphylococ-
cus aureus/epidermidis/saprophyticus,Pseudomonas aerug-
inosa, Acinetobacter and against 50% E. coli. The MIC of the
extract against all the bacteria was 20mg/ml.
Conclusion: This study demonstrated that methanolic
extract of T. catappa have excellent antibacterial activity
against most of bacteria isolated from burn wound infec-
tions and its effect is more better than selective antibiotics.
However, we need more investigation in vitro and in vivo.
doi:10.1016/j.ijid.2008.05.1079
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An AUC Based Method for Aminoglycoside Dosing Adjust-
ing for Drug Excretion During Infusion and Allowing Early
Recognition of Drug Accumulation
M.R. Loewenthal
John Hunter Hospital, Newcastle, Australia
Background: Once daily aminoglycoside dosing is now
standard. Area Under the curve (AUC) is the best predic-
tor of bacterial killing and toxicity. Formulas or applications
based on two concentration measurements are widely used
to optimise the AUC. Published methods do not account for
excretion during the infusion which varies greatly with infu-
sion duration. Drug accumulation may not be apparent from
the AUC calculated after an initial inappropriately small
dose. Formulas simple enough to be put on any spreadsheet
application or handheld device were developed to deal with
these problems.
Methods: Excretion during infusion and the effect of
impaired excretion were restated as linear differential
equations which have standard solutions. These formulas
were then applied to a set of data used previously to dose
cystic ﬁbrosis inpatients based on published AUC formulas.
This allowed recalibration of the target value. This new tar-
get was then applied to simulated data (1) derived from
our database of cystic ﬁbrosis home therapy patients who
administer their doses over 5min and (2) for patients with
impaired renal function. The formulas are supplied on the
poster and can be freely used
Results: The target AUC was recalibrated from 110 to
100mgh/l. An estimated 50% of home therapy cystic ﬁbrosis
patients had initial AUCs more than 10% above the new tar-
get. This increased to 64% after dosage adjustment based on
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the older method. Potential for drug accumulation was more
readily apparent in the simulated data using the new formu-
las. The spreadsheets used for the two methods appeared
practically identical.
Conclusion: Consideration should be given to using these
AUC formulas and adjusted targets unless all infusions are
given strictly over 30min.
doi:10.1016/j.ijid.2008.05.1080
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Activity of Tigecycline against Clinical Pathogens Col-
lected in Indonesia (2006)
J.D. Turnidge1,∗, J.M. Bell 1, D. Subekti 2, R.N. Jones3, I.
Yusuf4, L. Kusumawati5, M.J. Dowzicky6
1 Women’s and Children’s Hospital, Adelaide, Australia
2 ALERTAsia Foundation, Jakarta, Indonesia
3 JMI Laboratories, North Liberty, IA, USA
4 Hasanudin Hospital, Makassar, Indonesia
5 Haji Adam Malik Hosp, Medan, Indonesia
6 Wyeth Pharmaceuticals, Collegeville, PA, USA
Background: There are no published information on tige-
cycline potency and spectrum from isolates from Indonesia.
As a component of the SENTRY Antimicrobial Surveillance
Program (Asia-Paciﬁc Region), we evaluated the activity
of tigecycline tested against recent (2006) isolates from
Indonesia by reference MIC methods.
Methods: Non-duplicate strains were consecutively col-
lected from three medical centres in Indonesia. All isolates
were tested against tigecycline using validated commercial
broth microdilution panels (TREK Diagnostics), with con-
current acceptable quality control and CLSI interpretations
(M100-S18) for comparison agents. Tigecycline breakpoints
published by the United States - Food and Drug Adminis-
tration were applied for each indicated species or genus,
and the proposed/provisional Acinetobacter spp. breakpoint
(≤2mg/L) per Jones et al. (2007) was applied
Results: A total of 383 (307 Gram-negative and 76 Gram-
positive) isolates were evaluated. Tigecycline was highly
active against the top 10 most frequently isolated non-
pseudomonal pathogens which comprised 82% of all strains.
The highest tigecycline MIC90 results (2mg/L were recorded
for non-indicated species, Proteus-Providencia. P. aerug-
inosa was also not signiﬁcantly inhibited by tigecycline
(MIC90, >8mg/L; data not shown)
Conclusions: Tigecycline demonstrated excellent activity
against all the commonly isolated pathogens from Indonesia,
including those being multidrug-resistant to other antimi-
crobial classes. Tigecycline shows promise for therapy of
indicated, antimicrobial-resistant species in this nation and
indeed, the entire Asia-Paciﬁc region.
doi:10.1016/j.ijid.2008.05.1081
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Tigecycline Activity Against Isolates from Medical Centers
Located in China, Hong Kong and Taiwan (2006): A SENTRY
Antimicrobial Surveillance Program Report
M. Chen1, J.M. Bell 2, J.D. Turnidge2, R.N. Jones3,∗, M.J.
Dowzicky4
1 Peking Union Medical College Hospital, Beijing, China
2 Women’s and Children’s Hospital, Adelaide, Australia
3 JMI Laboratories, North Liberty, IA, USA
4 Wyeth Pharmaceuticals, Collegeville, PA, USA
Background: Tigecycline is a glycylcycline class agent
recently introduced into clinical practice worldwide as an
alternative therapy for various evolving multidrug-resistant
(MDR) bacterial infections. China, Hong Kong (HK) and Tai-
wan medical centers (14) were monitored in 2006 by the
SENTRY Program for tigecycline spectrum/susceptibility and
compared to more than 25 agents.
Methods: CLSI methods were used for testing 2,595 iso-
lates with US-FDA (tigecycline product package insert) and
CLSI (M100-S18) breakpoints applied. Resistance phenotypes
were screened per CLSI M100-S18 and genotypic-resistances
by sequencing when required. Tigecycline was not active
against P. aeruginosa (MIC50, >4g/ml), data not shown
Results: Among 2,595 strains processed, the most fre-
quently tested pathogens and resistance patterns were:
S. aureus (545, 40% MRSA) > E. coli (366, 52% ESBL)>
K. pneumoniae (265, 33% ESBL) > E. faecalis (218,
linezolid resistance detected) > A. baumannii (211,
29% carbapenem-resistant) >S. pneumoniae (175, 27/80%
penicillin/macrolide-resistant) > E. faecium (169, 2.4%
VanA-type glycopeptide resistance). Fluoroquinolone resis-
tance was very high among E. coli (64%), K. pneumoniae
(21%) and A. baumannii (62%). MRSA rates varied by
nation: Hong Kong and China (38%) and Taiwan (69%),
but oxacillin resistance did not effect tigecycline activ-
ity. Metallo--lactamases were noted in Enterobacteriaceae
(<1%). Tetracycline resistance was frequent (30—86%) in
Gram-positive and -negative organisms; but no tigecycline-
resistant or non-susceptible strains were detected among
indicated species except for enterococci (2.3%)
Conclusions: Tigecycline retained high activity and treat-
ment potential against MDR pathogens tested from China,
Hong Kong and Taiwan. Continued monitoring of the tigecy-
cline class agents in these nations appears prudent as the
glycylcyclines become widely used.
doi:10.1016/j.ijid.2008.05.1082
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Antimicrobial Activity of Tigecycline Tested against Con-
temporary Bacterial Isolates Collected in Australia (2006)
J.M. Bell 1,∗, J.D. Turnidge1, R.N. Jones2, M.J. Dowzicky3
1 Women’s and Children’s Hospital, Adelaide, Australia
2 JMI Laboratories, North Liberty, IA, USA
3 Wyeth Pharmaceuticals, Collegeville, PA, USA
Background: Tigecycline has been marketed in Australia
for over one year. As part of the SENTRY Antimicrobial
Surveillance Program (Asia-Paciﬁc Region), we evaluated the
